MANAGEMENT
Barbara S. Fox, Ph.D., Chief Executive Officer
Dr. Fox is an experienced entrepreneur and scientist. She was founder, President and Chief Scientific Officer of Recovery Pharmaceuticals, a company developing and marketing medications for the treatment of addiction. Prior to founding Recovery Pharmaceuticals in 1998, she was Vice President, Immunology at ImmuLogic Pharmaceutical Corp. She joined ImmuLogic in 1993, having served on the faculty of the University Maryland School of Medicine, Baltimore, as Associate Professor of Medicine with tenure in the Division of Rheumatology and Clinical Immunology, Dept. of Medicine. Dr. Fox received her BA in Chemistry from Bryn Mawr College and her Ph.D. in Chemistry from MIT. Dr. Fox trained as a post-doc in cellular immunology at the NIH.
David C. Dlesk, Chief Operating Officer
David Dlesk is an entrepreneurial life sciences senior executive with experience in general management, new business development, product development, manufacturing and sales. He has held corporate officer positions with two public biotech companies, including Biogen, where as Vice President of Operations he helped launch Avonex which has grown to be a $2 billion drug. He served as the President of Terumo Medical Corporation, the $200 million North American operating division of Terumo Corporation. He has served as CEO in four start-ups, including Recovery Pharmaceuticals, where he worked with Dr. Fox. Mr. Dlesk spent the first 13 years of his career with Baxter Healthcare Corporation, leaving as Director of Venture Technology. Mr. Dlesk received B.S. and M.S. degrees in Industrial Engineering from the University of Illinois, Urbana-Champaign.
David Poorvin, Ph.D., Chief Business Officer
Dr. Poorvin is President of his own consulting firm and serves on the boards of several biotech companies. Most recently, he was an Executive-in-Residence at Oxford Bioscience Partners. Before working at OBP, Dr. Poorvin retired from Schering-Plough Corporation as Vice President of Business Development. Prior to his 14 years in Business Development, Dr. Poorvin held positions of Director of Clinical Research at Schering-Plough and Pfizer Pharmaceuticals. He was responsible for several NDA programs and product approvals at both companies, including such drugs as Procardia and Imdur. Dr. Poorvin started his career in the pharmaceutical industry at Lederle Laboratories, where he directed pre-clinical research in the cardiovascular area.
Eileen F. Bostwick, Ph.D., Vice President Product Development
Eileen Bostwick is an expert in the development of oral antibody products. She was VP, R&D at GalaGen Inc., a company that was spun out of Land O´Lakes to develop pharmaceutical products from bovine milk and colostrum. At GalaGen, she led the R&D, regulatory and clinical efforts to advance these products to human clinical testing. She managed all aspects of the development process, including immunizations and colostrum collection, QC and evaluation of raw materials, coordination of bulk manufacturing and analysis, establishment of product and process specifications, validation of analytical methods, development of preclinical testing protocols and interactions with the USDA, CFSAN and FDA. Since leaving GalaGen, she has been a consultant and VP, R&D at BioBalance Corp. Dr. Bostwick holds a Ph.D. in Animal Physiology from the University of Minnesota.
